ExpreS2ion Biotechnologies

ExpreS2ion Biotechnologies is a Danish biotechnology company headquartered in Hørsholm and listed on the Nasdaq First North Growth Market Sweden. The company focuses on the development of vaccines and immunotherapy products, with activities spanning biological research, vaccine candidates, and technologies intended to support the production and development of recombinant proteins. A central part of the company’s technology base is the ExpreS2 insect-cell expression system, which is used to produce recombinant proteins. The platform is associated with Drosophila S2 cells and is intended to provide a route for expressing proteins used in research, diagnostics, vaccine development, and other biotechnology applications. This platform-oriented approach gives ExpreS2ion a role both as a developer of its own therapeutic and prophylactic candidates and as a provider of enabling biological technology. The company became particularly visible during the COVID-19 pandemic through its participation in the PREVENT-nCoV consortium. The consortium brought together AdaptVac, a joint venture involving ExpreS2ion Biotechnologies and the University of Copenhagen spin-out NextGen Vaccines, together with Leiden University Medical Center, the Institute for Tropical Medicine Tübingen, the Department of Immunology and Microbiology at the University of Copenhagen, and the Laboratory of Virology at Wageningen University & Research. In March 2020, the consortium received a €2.7 million grant from the European Union’s Horizon 2020 programme to support development of a COVID-19 vaccine candidate. ExpreS2ion was allocated €0.88 million of that funding. The PREVENT-nCoV work illustrated the company’s strategy of combining its expression technology with academic and translational partners. Rather than operating solely as a conventional commercial vaccine manufacturer, ExpreS2ion has positioned itself as a biotechnology developer working through platform technology, research collaborations, and product candidates. Its activities have included vaccine research and immunotherapy development, while the company’s listed status has provided access to public-market financing and visibility in the Nordic life-sciences sector. Publicly available reference material identifies the company as active and based in Denmark, but the supplied sources provide limited detail about its complete product portfolio, current clinical pipeline, executive team, financial performance, and present commercial operations. Those areas therefore require verification against current company filings and corporate disclosures.

ExpreS2ion Biotechnologies is a Danish life-sciences company based in Hørsholm. Its business is centered on biotechnology platforms and product development in vaccines and immunotherapies. The company’s activities are connected to the use of recombinant-protein expression systems, particularly an insect-cell platform based on Drosophila S2 cells. The ExpreS2 platform is designed to enable expression of recombinant proteins. Such systems can be used in research and development, diagnostic work, vaccine-antigen production, and other applications requiring biologically relevant proteins. By maintaining a platform capability alongside its own development programmes, ExpreS2ion has operated at the intersection of enabling technology and therapeutic or prophylactic product development. The company’s public profile increased substantially during the COVID-19 pandemic. ExpreS2ion participated in the PREVENT-nCoV consortium through AdaptVac, a joint venture involving ExpreS2ion and NextGen Vaccines, a spin-out associated with the University of Copenhagen. Other consortium participants included Leiden University Medical Center, the Institute for Tropical Medicine Tübingen, the University of Copenhagen’s Department of Immunology and Microbiology, and the Laboratory of Virology at Wageningen University & Research. In March 2020, PREVENT-nCoV received €2.7 million from the European Union’s Horizon 2020 research and innovation programme for development of a COVID-19 vaccine candidate. The reference material identifies €0.88 million as the portion funded to ExpreS2ion. The programme demonstrated the company’s emphasis on collaborative vaccine research and on applying its biological technology in response to an urgent public-health need. ExpreS2ion is listed on the Nasdaq First North Growth Market Sweden, giving it a public-market presence in the Nordic biotechnology sector. The available reference material does not establish a complete chronology of its founding, leadership changes, clinical milestones, commercial products, or later strategic decisions. A current corporate filing review would be needed to document those matters reliably.

• 2020

  PREVENT-nCoV receives EU Horizon 2020 grant

  [1]ExpreS2ion Biotechnologiesen.wikipedia.org

  The PREVENT-nCoV consortium was awarded €2.7 million through the European Union’s Horizon 2020 programme for development of a COVID-19 vaccine candidate. ExpreS2ion was allocated €0.88 million of the grant.

A Nordic biotechnology developer combining insect-cell protein-expression technology with vaccine and immunotherapy research, often through academic, consortium, and translational partnerships.

• Recombinant-protein expression technology

  ExpreS2 expression platform

  The ExpreS2 platform uses Drosophila S2 insect cells to express recombinant proteins. It is intended for biotechnology applications including research, diagnostics, vaccine development, and production of proteins used in biological development programmes. The supplied reference material identifies the platform as a core part of ExpreS2ion’s technology base, but does not provide a complete current catalogue of commercial products or licensing arrangements.

• Vaccine development · 2020

  COVID-19 vaccine candidate programme

  ExpreS2ion participated in the PREVENT-nCoV consortium, which pursued development of a COVID-19 vaccine candidate using the capabilities of academic and biotechnology partners. The programme was supported by an EU Horizon 2020 grant awarded in 2020. The supplied sources do not establish the candidate’s final development status or commercial outcome.

1. 1ExpreS2ion Biotechnologiesen.wikipedia.org